OBJECTIVES: New data suggest that glioma stem-like cells (GSCs) and neural stem/progenitor cells (NSCs) may share common origins. GSCs drive tumor proliferation and appear to be resistant to classic chemotherapy, while the effects of chemotherapy on NSCs are not well studied. As the role of NSCs in learning and memory is increasingly recognized, we need to identify drugs that reduce neurotoxicity but are still effective against glial tumors. METHODS: We treated 3 human NSC cultures and multiple low- and high-grade GSC cultures with the commonly used agents temozolomide (TMZ) and cisplatin (CIS), and with 2 newer, promising drugs: the proteasome inhibitor bortezomib (BTZ) and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL). We measured cell survival, proliferation, cell death induction, and drug resistance markers. RESULTS: TMZ decreased NSC viability, while minimally affecting GSCs. TMZ induced NSC death, which was partially compensated for by increased proliferation. CIS had similar effects. The NSC's sensitivity to TMZ and CIS correlated with low expression of the multidrug resistance gene ABCG2, but not of MGMT or MSH1/MLH2. BTZ caused an 80%decrease in GSCs, while minimally affecting NSCs. GSCs had lower proteasome levels and activity after BTZ treatment. ERL treatment also decreased GSC numbers, but not NSC viability, which correlated with low EGFR expression in NSCs compared to GSCs. CONCLUSIONS: Newer chemotherapy agents ERL and BTZ are effective against GSCs yet produce minimal effects on NSCs, while the older drugs TMZ and CIS are more toxic for NSCs than for GSCs. The identification and testing of more selective drugs is clearly warranted.
OBJECTIVES: New data suggest that glioma stem-like cells (GSCs) and neural stem/progenitor cells (NSCs) may share common origins. GSCs drive tumor proliferation and appear to be resistant to classic chemotherapy, while the effects of chemotherapy on NSCs are not well studied. As the role of NSCs in learning and memory is increasingly recognized, we need to identify drugs that reduce neurotoxicity but are still effective against glial tumors. METHODS: We treated 3 human NSC cultures and multiple low- and high-grade GSC cultures with the commonly used agents temozolomide (TMZ) and cisplatin (CIS), and with 2 newer, promising drugs: the proteasome inhibitor bortezomib (BTZ) and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL). We measured cell survival, proliferation, cell death induction, and drug resistance markers. RESULTS:TMZdecreased NSC viability, while minimally affecting GSCs. TMZ induced NSC death, which was partially compensated for by increased proliferation. CIS had similar effects. The NSC's sensitivity to TMZ and CIS correlated with low expression of the multidrug resistance gene ABCG2, but not of MGMT or MSH1/MLH2. BTZ caused an 80%decrease in GSCs, while minimally affecting NSCs. GSCs had lower proteasome levels and activity after BTZ treatment. ERL treatment also decreased GSC numbers, but not NSC viability, which correlated with low EGFR expression in NSCs compared to GSCs. CONCLUSIONS: Newer chemotherapy agents ERL and BTZ are effective against GSCs yet produce minimal effects on NSCs, while the older drugs TMZ and CIS are more toxic for NSCs than for GSCs. The identification and testing of more selective drugs is clearly warranted.
Authors: Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Surasak Phuphanich; Jeffrey G Supko; Kathryn A Carson; Stuart A Grossman; L Burt Nabors; Tom Mikkelsen; Glenn Lesser; Steve Rosenfeld; Serena Desideri; Jeffrey J Olson Journal: J Neurooncol Date: 2010-03-08 Impact factor: 4.130
Authors: Julio E Diestra; George L Scheffer; Isabel Català; Marc Maliepaard; Jan H M Schellens; Rik J Scheper; Jose R Germà-Lluch; Miguel A Izquierdo Journal: J Pathol Date: 2002-10 Impact factor: 7.996
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Philip H Schwartz; Peter J Bryant; Tannin J Fuja; Hailing Su; Diane K O'Dowd; Henry Klassen Journal: J Neurosci Res Date: 2003-12-15 Impact factor: 4.164
Authors: Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Shengwen Calvin Li; Long T Vu; Hector W Ho; Hong Zhen Yin; Vic Keschrumrus; Qiang Lu; Jun Wang; Heying Zhang; Zhiwei Ma; Alexander Stover; John H Weiss; Philip H Schwartz; William G Loudon Journal: Cancer Cell Int Date: 2012-09-20 Impact factor: 5.722
Authors: Daniela A Bota; Daniela Alexandru; Stephen T Keir; Darell Bigner; James Vredenburgh; Henry S Friedman Journal: J Neurosurg Date: 2013-10-04 Impact factor: 5.115